PFE Pfizer Inc: Net earnings per share growth forecast for next year

Brandmark of Pfizer Corp (PFE)

Pfizer Inc. (PFE) profitability is subject to intense patent battles and pressure from generics. The forward net income trend clearly demonstrates a shift in market expectations, where the parameter value equals -3.10. The behemoth is currently restructuring its R&D toward oncology, leveraging global distribution capabilities and the acquisition of promising biotech startups to solidify its monopoly status.

PFE: Pfizer Corporation Net earnings per one share growth forecast for next year 07/04/2022 - 11/10/2026

pfizer.com (PFE) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Stock Price Pfizer Corporation|PFE - Analyst Median Target
- company stock capitalization data:
Market Value Pfizer|PFE - Business Value
- company book value details:
Book Value per Share Pfizer|PFE - Book Value of Business|Market Value to Book Value Ratio pfizer.com|PFE - Total Asset Value of Company
- debt obligations and liquidity statistics:
Total Debt to Capital Pfizer Inc.|PFE - Long-Term Liabilities to Equity|Short-Term Debt to Capital Pfizer|PFE - Company Total Debt Obligations|Debt to Book Value Pfizer|PFE - Long-Term Liabilities|Company Short-Term Debts Pfizer|Quick Liquidity pfizer.com
- earnings and valuation multiples information:
PFE - Final Profit|Future Profit Pfizer Inc.|PFE - Company Value to Net Income|Forward P/E Multiple Pfizer Inc.|PFE - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pfizer|PFE - Operating profit before amortization|Net earnings per share (EPS TTM) Pfizer|PFE - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months pfizer.com|PFE - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Pfizer Inc.
Initial company analysis:Pfizer Corporation
Finished products of pfizer.com

Pfizer Inc. (PFE) is currently transforming its R&D strategy, shifting its focus toward oncology drugs following the decline in revenues from COVID-19 products. This metric measures the average expected growth rate of earnings per share, directly impacting the calculation of a fair P/E ratio. The narrowing range of forecasts signals that the market has reached a consensus regarding future cash flows. By analyzing changes in the consensus estimate for net profit growth, an investor can identify the moment institutional players revalue the business.

Who Pfizer Inc. competes with

LLY (Eli Lilly & Co.) - Earnings growth forecast for next year|AbbVie Corp. (ABBV) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year AstraZeneca PLC (AZN)|novartis.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year MRK (Merck)|Net earnings per one share growth forecast for next year Novo Nordisk AS|AMGN - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year SNY|BMY: Earnings growth forecast for next year|Net earnings per share change forecast for next year GSK (GlaxoSmithKline)|TAK (Takeda) - Earnings growth forecast for next year|Teva Pharmaceutical Industries Limited (TEVA) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year RDY (Dr. Reddy's Lab)|VTRS: Net earnings per share change forecast for next year|Earnings growth forecast for next year ROIV (Roivant Sciences Ltd.)|zailaboratory.com (ZLAB) - Expected net earnings per share growth next year|BHC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year COSM (Cosmos Health, Inc.)